Hepatocellular carcinoma (HCC) usually develops in chronically damaged liver. We investigated hepatic reserves during chemotherapy of patients with advanced HCC and compensated liver function to evaluate the effect on patients' outcomes of maintaining hepatic reserve after chemotherapy. We retrospectively reviewed the medical records of 190 patients with Child-Pugh A with advanced HCC who were treated with sorafenib or hepatic arterial infusion chemotherapy (HAIC). We investigated the Child-Pugh score and albumin-bilirubin grade for hepatic reserve, and evaluated the effect of the change in Child-Pugh scores on patients' outcomes. Subjects were treated with sorafenib (n = 59) or HAIC (n = 131). Of patients with Child-Pugh data, 66.7% maintained or improved their Child-Pugh score after 4 weeks. Treatment with HAIC was the only factor that significantly contributed to maintaining Child-Pugh scores after 4 weeks. The overall survival of patients with a higher Child-Pugh score after 4 weeks was shorter than that of patients whose Child-Pugh classification was unchanged. Multivariate analysis demonstrated that an increased Child-Pugh score after 4 weeks was one of the independent unfavorable prognostic factors. The change of hepatic reserve as a function of albumin-bilirubin grade did not significantly correlate with patients' outcomes. Maintaining the Child-Pugh score during chemotherapy benefits the outcomes of patients with advanced HCC, even those with sufficient hepatic reserve.

Keywords:
Hepatic reserve, Child-Pugh score, Hepatic arterial infusion chemotherapy, Sorafenib, Hepatocellular carcinoma
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2.
Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, et al: Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 2014;60:1674-1685.
3.
Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, et al: Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012;57:1244-1250.
4.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
5.
Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, et al: Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011;81:281-290.
6.
D'Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-231.
7.
Terashima T, Yamashita T, Arai K, Kawaguchi K, Kitamura K, Yamashita T, et al: Response to chemotherapy improved hepatic reserve for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis. Cancer Sci 2016;107:1263-1269.
8.
Bruix J, Sheman M; Practice Guidelines Committee, American Association for the study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
9.
Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, Arai K, et al: Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res 2015;45:949-959.
10.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-558.
11.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
12.
Kaneko S, Ikeda K, Matsuzaki Y, Furuse J, Minami H, Okayama Y, et al: Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol DOI: 10.1007/s00535-016-1173-5.
13.
Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, et al: Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014;44:1179-1185.
14.
Terashima T, Yamashita T, Takata N, Nakagawa H, Toyama T, Arai K, et al: Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res 2016;46:650-656.
15.
Terashima T, Yamashita T, Horii R, Arai K, Kawaguchi K, Kitamura K, et al: Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC Cancer 2016;16:338.
16.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, et al: Alternative treatments in advanced hepatocellular carcinoma patientes with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget DOI: 10.18632/oncotarget.
17.
Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, et al: Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. J Dig Dis 2015;16:505-512.
18.
Shiozawa K, Watanabe M, Ikehara T, Kogame M, Matsui T, Okano N, et al: Comparison of sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a propensity score matching study. Hepatogastroenterology 2014;61:885-891.
19.
Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al: Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer System. Hepatology 2013;57:112-119.
20.
Chen L, Chen Y, Wang X, Li H, Zhang H, Gong J, et al: Efficacy and safety of oral branched-chain amino acid supplementataion in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutr J 2015;14:67.
21.
Kanekawa T, Nagai H, Kanayama M, Sumino Y: Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. Cancer Chemother Pharmacol 2014;75:899-909.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.